Author

Matteo Fila

Institutions: Mayo Clinic, Humanitas University, Mayo Clinic Hospital, IRCCS Humanitas Research Hospital

Observed institutions: Mayo Clinic, Humanitas University, Mayo Clinic Hospital, IRCCS Humanitas Research Hospital

ORCID: 0009-0009-3769-0475

Observed ORCID: 0009-0009-3769-0475

OpenAlex ID: A5133084535

Circulating tumor DNA (ctDNA) in early-stage NSCLC: a new frontier in precision oncology

2026 · Silvia Masini, Matteo Fila, et al. · Journal of Cancer Metastasis and Treatment · 1

Data from Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry

2026 · Arianna Marinello, Julia K. Rotow, et al.

Supplementary Data1 from Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry

2026 · Arianna Marinello, Julia K. Rotow, et al.

Retreatment with First-Generation Selective RET Inhibitors in RET -Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry

2026 · Arianna Marinello, Julia K. Rotow, et al. · Clinical Cancer Research

Works count: 4

Citation count: 1

H-index: 1

I10-index: